Your browser version may not work well with NCBI's Web applications. More information here...
1: Pharmacogenomics. 2008 Oct;9(10):1547-50.Click here to read Links
Comment on:
Ophthalmology. 2008 Jun;115(6):1019-25.

CFH and LOC387715/ARMS2 genotypes and antioxidants and zinc therapy for age-related macular degeneration.

Lee AY, Brantley MA Jr.

Department of Ophthalmology and Visual Sciences, Campus Box 8096, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.

EVALUATION OF: Klein ML, Francis PJ, Rosner B et al.: CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115(6), 1019-1025 (2008). The late form of age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the elderly, with a complex etiology involving genetic and environmental factors. Recently, multiple distinct genetic susceptibility loci for AMD have been identified. Specifically, variations in the Complement Factor H (CFH) gene as well as the LOC387715/ARMS2 gene have been shown to be strongly associated with AMD. The Age-Related Eye Disease Study (AREDS) is a large multicenter, placebo-controlled, randomized clinical trial that showed that a combination of zinc and antioxidants reduced progression to late-stage AMD. In the present study, the authors found that within AREDS there was a significant interaction between zinc and CFH genotypes, indicating that CFH genotypes may be predictive of treatment response to zinc supplementation.

PMID: 18855541 [PubMed]